SCHEMBL23747710

SCHEMBL23747710

COc1ccc(CNC(=O)Nc2ccc(OCCc3ccccn3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.63
NPC1 O15118 3/20 0.63
SMN1; SMN2 Q16637 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
NAMPT P43490 3/20 0.54
KMT2A Q03164 4/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
PPARA Q07869 1/20 0.53
MEN1 O00255 2/20 0.53
HTT P42858 1/20 0.53
ROCK2 O75116 1/20 0.53
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30361513 1.00 RAB9A (0.63) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1
SCHEMBL30361474 0.89 CNR1 (0.65) RAB9ANPC1SMN1; SMN2L3MBTL1NAMPT
SCHEMBL26547729 0.89 RAB9A (0.63) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1
SCHEMBL23747711 0.89 CNR1 (0.65) RAB9ANPC1SMN1; SMN2L3MBTL1NAMPT
SCHEMBL20379320 0.85 L3MBTL1 (0.74) RAB9ANPC1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL26101434 0.84 RAB9A (0.64) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1
SCHEMBL11617438 0.83 CA12 (0.71) RAB9ANPC1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL26101473 0.82 RAB9A (0.58) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1
SCHEMBL26098819 0.81 RAB9A (0.69) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1
SCHEMBL17916794 0.80 SMN1; SMN2 (0.88) RAB9ANPC1SMN1; SMN2L3MBTL1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
WO-2021159015-A1 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 RAB9A 807/4885NPC1 463/4885SMN1; SMN2 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.